Comparison of the Onset and End of Specific and Major Side Effects in Iranian Teenage Participants Vaccinated With COVID-19 Vaccine: Sinopharm and Soberana.
Adolescent
Adverse Effect
COVID-19
Children; Pediatric
Delayed
Early
Safety
Sinopharm
Soberana
Vaccination
Journal
Medical journal of the Islamic Republic of Iran
ISSN: 1016-1430
Titre abrégé: Med J Islam Repub Iran
Pays: Iran
ID NLM: 8910777
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
05
2022
medline:
1
5
2023
pubmed:
1
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
Clinical trials were conducted on children on side effects after vaccination. We tried to assess the frequency and onset of the main symptoms in children who were vaccinated. We aimed to evaluate early and delayed adverse effects after coronavirus disease 2019 (COVID-19) vaccine among Iranian pediatrics and adolescents in a national survey. This cross-sectional study included people <18 years who received the Soberana (PastoCoVac) and Sinopharm vaccines since 2021. The basic information was gender, age, type of vaccine, and reaction after vaccination besides the main events that occurred for them. The required data were collected via a predetermined checklist by trained interviewers through phone calls by their parents or legal guardians. The independent t test and Fisher exact test were used. P values less than 0.05 were considered significant. A total of 11,042 participants (age range, 10-18 years) consisting of 5374 boys (47.8%) and 5768 girls (52.2%) were studied and 88.1% of the children (n = 9727) were vaccinated by Sinopharm and 11.9% (n = 1315) by Soberana. The data of kidney-related side effects had delayed improvement of side effects after the Sinopharm compared with the Soberana vaccines ( The cardiovascular and hematological, joint-related (non-neurologic musculoskeletal) and dermatological side effects after the Soberana vaccine appear earlier and end later compared with the Sinopharm vaccine. Improvement of renal side effects in the Sinopharm vaccine group and improvement of neurological and respiratory side effects in the Soberana vaccine group occurred with delay compared with other vaccines.
Sections du résumé
Background
UNASSIGNED
Clinical trials were conducted on children on side effects after vaccination. We tried to assess the frequency and onset of the main symptoms in children who were vaccinated. We aimed to evaluate early and delayed adverse effects after coronavirus disease 2019 (COVID-19) vaccine among Iranian pediatrics and adolescents in a national survey.
Methods
UNASSIGNED
This cross-sectional study included people <18 years who received the Soberana (PastoCoVac) and Sinopharm vaccines since 2021. The basic information was gender, age, type of vaccine, and reaction after vaccination besides the main events that occurred for them. The required data were collected via a predetermined checklist by trained interviewers through phone calls by their parents or legal guardians. The independent t test and Fisher exact test were used. P values less than 0.05 were considered significant.
Results
UNASSIGNED
A total of 11,042 participants (age range, 10-18 years) consisting of 5374 boys (47.8%) and 5768 girls (52.2%) were studied and 88.1% of the children (n = 9727) were vaccinated by Sinopharm and 11.9% (n = 1315) by Soberana. The data of kidney-related side effects had delayed improvement of side effects after the Sinopharm compared with the Soberana vaccines (
Conclusion
UNASSIGNED
The cardiovascular and hematological, joint-related (non-neurologic musculoskeletal) and dermatological side effects after the Soberana vaccine appear earlier and end later compared with the Sinopharm vaccine. Improvement of renal side effects in the Sinopharm vaccine group and improvement of neurological and respiratory side effects in the Soberana vaccine group occurred with delay compared with other vaccines.
Identifiants
pubmed: 37123336
doi: 10.47176/mjiri.37.15
pmc: PMC10134091
doi:
Types de publication
Journal Article
Langues
eng
Pagination
15Informations de copyright
© 2023 Iran University of Medical Sciences.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Med J Islam Repub Iran. 2021 May 17;35:63
pubmed: 34277500
Exp Dermatol. 2021 Sep;30(9):1233-1253
pubmed: 33977531
Clin Case Rep. 2022 Apr 26;10(4):e05775
pubmed: 35498347
Dermatol Ther. 2022 Jun;35(6):e15461
pubmed: 35316551
MMWR Morb Mortal Wkly Rep. 2021 Oct 22;70(42):1483-1488
pubmed: 34673751
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S455-S458
pubmed: 28404514
N Engl J Med. 2022 Jan 6;386(1):35-46
pubmed: 34752019
N Engl J Med. 2021 Dec 9;385(24):2241-2251
pubmed: 34379915
Lancet Infect Dis. 2021 Dec;21(12):1645-1653
pubmed: 34197764
Arch Dis Child. 2022 Mar;107(3):e16
pubmed: 34740880
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
J Cutan Pathol. 2021 Oct;48(10):1266-1276
pubmed: 33978234
JAMA. 2021 Nov 23;326(20):2002
pubmed: 34812857
JAMA Netw Open. 2021 Dec 1;4(12):e2140364
pubmed: 34935921
J Med Virol. 2021 Feb;93(2):1057-1069
pubmed: 32761898
Vaccine. 2021 Sep 7;39(38):5333-5336
pubmed: 34393021
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Circulation. 2021 Aug 10;144(6):471-484
pubmed: 34281357
J Med Virol. 2022 Oct;94(10):4890-4900
pubmed: 35758760
Exp Clin Transplant. 2021 Jul;19(7):627-634
pubmed: 33877041
Ann Intern Med. 2021 Feb;174(2):221-228
pubmed: 33090877
Pediatr Allergy Immunol. 2021 Jan;32(1):9-16
pubmed: 33113210
Heart Lung Circ. 2021 Oct;30(10):1425-1429
pubmed: 34340927
Vaccine. 2021 Jan 22;39(4):667-677
pubmed: 33342635
Children (Basel). 2021 Jul 18;8(7):
pubmed: 34356586
Vaccines (Basel). 2021 Nov 09;9(11):
pubmed: 34835228
Lancet Respir Med. 2020 Dec;8(12):1159
pubmed: 33129420
Int J Infect Dis. 2020 Sep;98:14-15
pubmed: 32585285
Pediatr Pulmonol. 2020 Oct;55(10):2565-2575
pubmed: 32725955
J Med Virol. 2021 Dec;93(12):6588-6594
pubmed: 34270094
JAMA Surg. 2019 Apr 1;154(4):319-326
pubmed: 30601881
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803